Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Statins Usage in Croatia: The Effects of Introducing Generics (CROSBI ID 550284)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Vitezić, Dinko ; Matana Kaštelan, Zrinka ; Buble, Tonči ; Mršić-Pelčić, Jasenka ; Rosović, Vesna ; Kovačević, Miljenko ; Simonić, Ante Statins Usage in Croatia: The Effects of Introducing Generics // Canadian journal of clinical pharmacology. 2008. str. 740-741

Podaci o odgovornosti

Vitezić, Dinko ; Matana Kaštelan, Zrinka ; Buble, Tonči ; Mršić-Pelčić, Jasenka ; Rosović, Vesna ; Kovačević, Miljenko ; Simonić, Ante

engleski

Statins Usage in Croatia: The Effects of Introducing Generics

The treatment of hypercholesterolemia with statins (or HMG-CoA reductase inhibitors) has an important place in the prevention of atherosclerosis. The aim of this study was to detect changes in statins usage and the effects of generic statins introduction on the national reimbursement list. Drug utilization and financial expenditure data were analyzed for statins prescribed by GPs. The data were obtained from the Croatian National Health Insurance Institute for the six-year period (2001-2006). Drug utilization data are presented in defined daily doses/1000 inhabitants/day (DDD/1000), while financial expenditure data are presented in Euros. In the period 2001-2006, the usage of statins increased 4.48 times (from 10.01 to 44.86 DDD/1000) while the related expenditure increased 3.16 times. The highest growth of 109.38% was in 2003 (in comparison to 2002) i.e. from 9.82 to 20.56 DDD/1000, and the related expenditure increased 1.8 times. The share of generic drugs increased from 1.01% to 45.38%. For the entire period simvastatin and atorvastatin remained not only the most frequently prescribed statins (ranging from 86.30% in 2001 to 95.97% in 2004), but also had the highest financial share (83.96% in 2001 to 90.27% in 2006). Share of generic simvastatin and atorvastatin increased from 1.17% to 49.64%. The usage of statins in Croatia increased considerably during the investigated period, especially in 2003 as a result of a legal change (the new Insurance Act) with the introduction of supplementary health insurance. The introduction of generic statins and restrictive measures on Croatian drug market slowed down the increase of financial expenditure.

statins; generics; usage; financial expenditure; national reimbursement list

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

740-741.

2008.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Canadian journal of clinical pharmacology

1198-581X

Podaci o skupu

World Conference on Clinical Pharmacology and Therapeutics (9 ; 2008)

poster

27.07.2008-01.08.2008

Quebec, Kanada

Povezanost rada

Kliničke medicinske znanosti, Javno zdravstvo i zdravstvena zaštita

Indeksiranost